Although ERα expression might play a prominent role in the development of ovarian tumors, the application of estrogen-blocking agents (such as tamoxifen) in the therapy of ovarian cancer has achieved mixed results [16,17]. This evidence concerns the gene ESR1 and ovarian neoplasm.